Farrukh T. Awan, MD

Associate Professor and Director of Lymphoid Malignancies Program at UTSW
The University of Texas Southwestern

Poster(s):

• 1417 - Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety

• 1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study

• 1715 - Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies